SUPP RT AKI

<u>Strategy for UPtake of PrOcesses for Recognizing and Responding To Acute Kidney Injury</u>

Matthew James MD PhD, Nephrologist, University of Calgary Meha Bhatt MSc, Project Coordinator, University of Calgary







UNIVERSITY OF CALGARY CUMMING SCHOOL OF MEDICINE


Overview: Why, What & How?

- Why is it important to recognize and manage AKI early?
- What will be done as part of the initiative?
- **How** will it be implemented?

• Questions and next steps

Why?: Rising Incidence of Acute Dialysis

N Siddiqui, SG Coca, PJ Devereux, AK Jain, L Li, J Luo, CR Parikh, M Paterson, HT Philbrook, R Wald, M Walsh, AX Garg CMAJ 2012



Why?: AKI, hospitalization, and costs in Alberta


	Alberta 02 to April, 2009 hospitalized adults			etermined	A	14 days KI: KIN-determine v peak Cr	ed de	90 days ecovery: etermined by r after D/C
Results		N	<u>A</u>	hospital mortality	t one ye		Ļ	hospital cost
65	No AKI	206,650	(86%)	3%	12 ^s		days	\$9,444 CAD
Ì	Stage 1	25,495	(11%)	12%	25	% 11.4	days	\$12,356 CAD
ð,	Stage 2	4,598	(2%)	27%	41	% 12.8	days	\$14,370 CAD
\$	Stage 3	2,493	(1%)	34%	47	% 13.7	days	\$14,822 CAD
	Stage 3 + Dialysis	s 670	(0.3%)	50%	56	% 16.5	days	\$24,260 CAD

Conclusion Severity of AKI, need for dialysis, and lack of kidney recovery are associated with significant health care costs in hospitalized patients and persist a year following admission.

David Collister, Neesh Pannu, Feng Ye, Matthew James, Brenda Hemmelgarn, Betty Chui, Braden Manns, Scott Klarenbach. Healthcare Costs Associated with Acute Kidney Injury, CJASN doi:10.2215/CJN.00950117.



Why?: AKI After Major Surgery in Calgary



Why?: The Clinical Challenge


Early intervention begins with early recognition

- Symptoms absent at early stage
- Scr changes indicating AKI occur in ~40% before SCr "abN"
- Possible warning sign (not always): reduced urine production
- Fluid balance and medication effects are modifiable: Reduced intake, vomiting, edema, low/high blood pressure, NSAIDs


Renal function can continue to decline, unless AKI is recognized and treated

Why?: Health Impact on Patients

- Adverse outcomes include need for dialysis, chronic kidney disease and end-stage renal disease, mortality¹
- 8.8 times greater risk of developing chronic kidney disease in patients who develop in-hospital AKI²
- **12.6 times greater risk of mortality** in perioperative patients with AKI³



What?: The SUPPORT AKI Initiative



Recognize

• Recognize AKI at its onset and factors contributing to progression

Respond

• Early use of IV fluid therapies, medication management, and appropriate monitoring

Refer

 Resources to guide care and referral when needed

Outcome: Reverse injury, Reduce avoidable harm, Restore renal function

What?: The SUPPORT AKI Initiative

James *et al. Canadian Journal of Kidney Health and Disease* 2014, **1**:20 http://www.cjkhd.org/content/1/1/20



REVIEW



Open Access

Improving prevention, early recognition and management of acute kidney injury after major surgery: results of a planning meeting with multidisciplinary stakeholders

Matthew T James^{1,2,6*}, Elijah Dixon^{2,3}, Derek J Roberts^{2,3}, Rebecca Barry¹, Carlee Balint¹, Aleem Bharwani¹, William Don Buie³, Tomas Godinez⁴, Brenda R Hemmelgarn^{1,2}, John B Kortbeek³, Braden J Manns^{1,2}, Andria Marin³, Nairne Scott-Douglas¹, Henry Tom Stelfox^{2,4} and Neesh Pannu⁵

Intravenous Therapies for Hypovolemic Patients

- ✓ Isotonic crystalloids (0.9% NaCl or Ringer's Lactate) are preferred for initial management for expansion of intravascular volume
- Diuretics are not recommended to treat AKI, except in the management of volume overload.
- Boluses of intravenous fluids are considered the most effective strategy for correcting hypovolemia.
 - Review volume administration safety concerns, determine risk for volume overload, & select bolus volumes
 - Administer repeat boluses as needed unless signs of volume overload/cardiorespiratory compromise are present

Medication Management

- Consider stopping flagged medications that affect kidney function
- Consider adjusting doses for renally cleared drugs for cases of persistent severe AKI (Stage 2 or Stage 3 AKI only)


Consult clinical pharmacist if needed

What?: The SUPPORT AKI Initiative



en Suema							
ic VL.		Alert	Created	Priority	Type	Comment.	
1	157,66	EZAKCAIet	2015-May-10 10-	орнон р	NARTENG		0+1
ets ensage paced	date) passo	tas met ciltera fo spon the serum c	STIGE 2 Aude Kidney'ls satistice dawn 20	6-Map-101904	0.00		
etermeto.	pressure or This patient	ed anothing maphes to carrient receivers	ment of Anale Kidney buy losis agents where pound pithe halowing medicatio	ole.			
	This parameter	ed anoiding maphra Lis cament receiving M ep. funcs entide infa	tons agents where possi	ole. No which may	29469 DE 2019 O		
heta: Uro	pressure an This patient Kolney inju celecoolb s	ed anothing maphes t is current receiver, pp. turos enside infla fp:	toni agerti uhere pocit gite fakoving medicato	ole. No which may	29469 DE 2019 O	walij Avoibilo i	n Acide

	-	**************************************	1	
	100	~	1	
	100	1	-	
		1		
	216	ALC: NOT THE REAL PROPERTY OF		
	1.44		100 C 10 C	
				1.00
				12
	1030	**************************************		1.00
		bernet denert		bedowie bestate
and the second second	and a local diversion of the local diversion	and the second second		
100111-010	Read and and and and and and and and and a	81 (m + 10 m +		
100-1103		100.000	-	
	Barrison	1100-1111		
	Parties.	12010		
	Description Billion Billion	115100		
And the second s	Barrison Biles Biles Biles			
		-	and	



AKI alerts

 Non-interruptive alerts in SCM based on Scr changes to identify patients at first onset of AKI and progression of severity stage

Medication alerts


 Flags medications that may be impacting kidney function or those requiring dose adjustment

AKI Dashboard

• Summarizes information on fluid balance, IV therapies, to guide early intervention.

AKI Order Sets

 Resource to guide the management of AKI and recommendations for consultation with specialists



atients		e Selected Patients
ily Avail New Orde Pati Pati Pati Pen Plar Priv REF Roo Rx \ Sou	m /erify rce iporary Location	Displayed Columns Patient Name Privacy Indicator Assigned Location Provider Family MD New Alerts New Besults New Documents Flag New Nurse Assigned Admit Date Care Level Service Visit Reason
	Add >>	Visit Status Visit Type << Remove

atients	0 Visit(s)	Save Selected Patients
nily Avai	nt List Column Configur ilable Columns w Orders	Displayed Columns Assigned Location
Ord Pat Per Pla Priv REI Roo RX Sou Ter	ter Rec ters Pending Review tient ID / Visit Number tient Tracking nding Status nned/Actual Discharge Date vacy Status PAC om Verify urce mporary Location Sign <u>A</u> dd >>	Forvider Family MD New Alerts New Results New Documents
		OK Cancel <u>H</u> elp

Current List: FMC	Acute Consult	S		•	Select /	All Patient	ts	16 Visit(s)	Sa	ve Selected	l Patie	nts)
Patient Name	Privacy Indicator	Assigned Location	Age	Provider	Flag New	New Alerts	Unack Alerts	New Orders	New Res	New Docu	То V	To Sign	ARO/M
	Normal											7	
	Normal											٣	
	Normal											٣	
	Normal											٣	Y
	Normal											٣	
	Normal											7	
	Normal											٣	
	Normal						•					٣	
	Normal											٣	
	Normal											٣	

Recognize: AKI Alerts

\c	Vi	D	Alert	Created	Priority	Туре	Comment	Scope
	\checkmark		STAGE 1 AKI Alert	2016-May-10 09:53	HIGH	WARNING		Chart
		STAG	E 1 AKI Alert					
		This	patient has met criteria for					
essag	e:	This hour	patient has met criteria for rs or 50% increase within 7	days) based upon the seru	m creatinir	ne value drawn.	2016-May-09 09:4	0:00
ert: essag kpand eferen	e:	This hour Curre	patient has met criteria for	days) based upon the seru nent of Acute Kidney Injury	m creatinir suggest e	ne value drawn.	2016-May-09 09:4	0:00
essag (pand	e:	This hour Curre press	patient has met criteria for rs or 50% increase within 7 ent guidelines for manager sure and avoiding nephroto patient is current receiving	days) based upon the seru ment of Acute Kidney Injury oxic agents where possible	m creatinir suggest e	ne value drawn: ensuring adequ	2016-May-09 09:44 ate volume status	0:00 s and blood


Recognize: Medication Alerts

Ac Vi D	Alert	Created	Priority	Туре	Comment	Scope
🖌 🖌 🖌 🗛 АКТ А	Alert	2016-May-13 13:1	HIGH	WARNING	test	Chart
ert: AKI Alert						
	DRUG EVENTS WARNI	NG FOR ACUTE KIDNEY INJ	URY			
				ast 48 bours 20	16-May-13 13:07:3	1
pand This patier	nt has developed STAC	GE 1 Acute Kidney Injury w	ithin the la			
rhis patier	nt has developed STAC	GE 1 Acute Kidney Injury w	ithin the la			
xpand This patier	nt has developed STAC	GE 1 Acute Kidney Injury w	ithin the la			
xpand This patier	nt has developed STAC	GE 1 Acute Kidney Injury w	ithin the la			
rhis patier	nt has developed STAC	GE 1 Acute Kidney Injury w	ithin the la			
eferences celecoxib o	nt has developed STAC ation may cause wors cap, metoLAZONE liqu	GE 1 Acute Kidney Injury w ening kidney function and	ithin the la	ally avoided in	Acute Kidney Inju	ry:
xpand This patier	nt has developed STAC	GE 1 Acute Kidney Injury w ening kidney function and	ithin the la	ally avoided in		ry:
tatus: Acknowledged	at has developed STAC ation may cause wors cap, metoLAZONE liqu By: Ji, Chen Ana	GE 1 Acute Kidney Injury w ening kidney function and	ithin the la	ally avoided in	Acute Kidney Inju	ry:
eferences celecoxib o	at has developed STAC ation may cause wors cap, metoLAZONE liqu By: Ji, Chen Ana	GE 1 Acute Kidney Injury w ening kidney function and	ithin the la	ally avoided in	Acute Kidney Inju	ry:


Recognize: AKI Dashboard

/īew: Acute Kidney Injury ▼ 1 week	▼ 2017-Dec-15 15:55 To 2017	-Dec-22 15:55							
AKI Stage			7 Day Creatinine Urea	Rectangular Snip			ealth Issues		
AKI Stage Date Onset	Creatinine Level		Creatinine LEVEL Urea			He	ealth Issue	Onset Date	Description
STAGE 3 AKI Alert 2017-Dec-19 02:3	1 379			379.0		=	Admitting Dx		
				364.0			recurrent diverticulitis	2017-Dec-07	recurrent diverticulitis
			360.0 - 351.0				Surg Procedure		
			330.0 -	\$33.0			2017/12/16-Laparotomy:Recto Sigmoid	2017-Dec-17	2017/12/16
			200.0		000.0		Sign Over		
			300.0 -		293.0		Dec 22	2017-Dec-08	62 y.o. female IgA
			270.958.0			-259.0 -	SignOverConslt1		
							Dec 16 - Stable	2017-Dec-13	62yo female with a previou
			24.0	23.8 23.2			Past History		
			22.0 - 21.5	•			Stress incontinence	2017-Aug-18	
			22.0				Diverticulosis	2017-Aug-18	
			20.0 -				Chronic loose stools/diarrhea NYD	2017-Aug-18	
			19.0				Duodenitis/gastritis 2 nsaid use	2017-Aug-18	
			18.0				HTN	2017-Aug-18	
				0.00	0.00		Obesity	2017-Aug-18	
			0:00 0:00 Dec-17-2017 Dec-18-2017	0:00 0:00 Dec-19-2017 Dec-20-2017	0:00 Dec-21-2017 De	0:00 ec-22-2017	NIDDM	2017-Aug-18	
AKI Specific Medications				IVs and Drips					2017-Dec-21 15:55 To 2017-Dec-22
Medication	Order Date	Status	Last Given	IV and Components		Rate	Units Status		Row Comment
MAY CAUSE AKI				+ IV Solution (mL)			active		0.9% NaCl
furosemide inj (Ordered as: LASIX inj) 40 mg IVPB /	2017-Dec-21 10:42	Active	2017-Dec-22 09:52						
furosemide inj 80 mg IV Q8H	2017-Dec-17 13:56	Discontinued	2017-Dec-18 06:11						
CLEARED BY KIDNEY									
dalteparin inj 5,000 unit(s) SUBCUTANEOUSLY q24h,	2017-Dec-16 22:13	Discontinued							
metoclopramide inj 10 mg IVPB q4h PRN nausea	2017-Dec-16 22:13	Active							
piperacillin / tazobactam inj (Each 2.25 g dose contains		Active	2017-Dec-22 12:23						
		D1 11 1	2017 0 10 02 02						
amoxicillin / clavulanate 500F tab (Each tablet	2017-Dec-13 13:07	Discontinued	2017-Dec-16 03:52						

Recognize: AKI Dashboard



Recognize: AKI Dashboard



Respond: AKI Order Set

				Intraven	ous Thera	pies					
Isotonic crystalloids are prefer include liver failure/suspected	red for initial i spontaneou	management for is bacterial perito	expansion o nitis, and bu	f intravascular volume in patien ms.	ts with AKI	Crystalloids are	preferred over o	colloid solutions in most scenarios - ex	ceptions may	2	
	Risk of Flui	id Overload Caus	sing Cardio-F	Respiratory Compromise							
		Lo	W No histo kidney d	y of heart failure. Left ventricul isease. No third spacing of fluid	ar ejection	fraction greater t	han 55%. No his	tory of chronic			
		Intermedia	Heart fai kidney d	Heart failure (mild systolic dysfunction). Left ventricular ejection fraction 45-55%. History of chronic kidney disease. Minor third spacing of fluids.							
	High H			istory of heart failure (moderate or severe dysfunction). Left ventricular ejection fraction less than 5%. History of advanced chronic kidney disease. Significant third spacing of fluids.							
	Select app	ropriate solution a	according to	risk for fluid overload							
	Select 0.	9% NaCl infusio	n: If intrava	scular expansion WITHOUT al	Ikalinization	L.					
			20	scular volume expansion WITH							
			a. In ning to	scuidi volume expansion vvim	1 dir.dil liza	Juri.					
Hypovolemic/Volume respon	Concerning and the second second										
Order	Bolus	Bolus Volume (mL)	Frequency	Adjustable Rate	Start Priority	Stop After		Advisory Note	Additional		
					1 minute						
-1 LOW risk - 2 item(s)		And a second sec									
LOW risk - 2 item(s)			once	Give over 15 to 30 minutes	STAT			Recommended: 250 to 1000 mL.	INITIAL bolus.		
	N N		once q1h	Give over 15 to 30 minutes Give over 15 to 30 minutes				Recommended: 250 to 1000 mL. Recommended: 250 to 1000 mL.	INITIAL bolus. REPEAT bolus		
0.9% NaCl infusion	Ø										
0.9% NaCl infusion 0.9% NaCl infusion	Ø				Routine						
0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i	item(s)		q1h once	Give over 15 to 30 minutes	Routine			Recommended: 250 to 1000 mL.	REPEAT bolus_		
0.9% NaCl infusion 0.9% NaCl infusion 10.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion	item(s)	P	q1h once Patient Care	Give over 15 to 30 minutes Give over 15 to 30 minutes	Routine			Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL	REPEAT bolus_		
0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion	item(s)	P	q1h once Patient Care	Give over 15 to 30 minutes	Routine	ets in the clinical		Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL	REPEAT bolus_		
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s)	item(s)	P	q1h once Patient Care Nease specif	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para	Routine	ets in the clinical		Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL	REPEAT bolus_	Frequency	Additional Information
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s) 0.9% NaCl infusion	item(s)	P	q1h once Patient Care Nease specif	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para	Routine STAT	ets in the clinical	communication	Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL	REPEAT bolus_	Frequency	Additional Information
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s) 0.9% NaCl infusion	item(s)	P	q1h once Patient Care Pease specif 0 0 0 0 Notify - 1	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para irder	Routine STAT		communication	Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL	REPEAT bolus	Frequency	Additional Information
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s) 0.9% NaCl infusion	item(s)	P	q1h once Patient Care Nease specific Notify - 1	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para irder	Routine STAT meter targe Who		communication	Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL.	REPEAT bolus	Frequency	Additional Information
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s) 0.9% NaCl infusion	item(s)	P	q1h once Patient Care Please specif C - Notify - 1 N Monitorin	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para Irder item(s) otify	Routine STAT meter targe Who		communication	Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL.	REPEAT bolus	Frequency	Additional Information Start prior to initiation of each bolus
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s) 0.9% NaCl infusion	item(s)	P	q1h once Patient Care Notify - 1 Notify - 1 Nonitorin Wonitorin	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para irder item(s) otify g - 2 item(s)	Routine STAT meter targe Who		communication	Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL.	REPEAT bolus		
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s) 0.9% NaCl infusion	item(s)	P	q1h once Patient Care Please specif O Notify - 1 Nonitorin Monitorin V V	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para inder item(s) otify g - 2 item(s) ital Signs	Routine STAT meter targe Who Attending		communication	Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL.	REPEAT bolus	q1h	Start prior to initiation of each bolus
0.9% NaCl infusion 0.9% NaCl infusion 0.9% NaCl infusion INTERMEDIATE risk - 2 i 0.9% NaCl infusion 0.9% NaCl infusion HIGH risk - 2 item(s) 0.9% NaCl infusion	item(s)	P	q1h once Patient Care Please specif O Notify - 1 Nonitorin Monitorin V V Monitorin Safety an	Give over 15 to 30 minutes Give over 15 to 30 minutes y fluid safety and efficacy para inder item(s) otify g - 2 item(s) ital Signs ionitor Output	Routine STAT meter targe Who Attending		communication	Recommended: 250 to 1000 mL. Recommended: 100 to 500 mL.	REPEAT bolus	q1h	Start prior to initiation of each bolus

Respond: AKI Order Set

fedication Safety					
Consider discontinuation of nephrotoxic nan or equal to Stage 2 AKI doubling s			on. Consider discontinuing or dose adjus	stment of renally cleared drugs for cases of persistent seve	ere AKI (e.g. greate
Order	Date Requested For		Reason for Referral	Referral Instructions	Additional Information
Pharmacist Consult - 1 item(s)	14102	Michael 10	New Concernence of the Concernen		1.00
Pharmacist Consult	T	Routine		 Routine requests will be followed up 	

Refer: AKI Order Set

Consults			
Consider discussing the mana	gement of AKI with a nephrologist when one or more of the f	ollowing are present:	
-	Possible diagnosis that may need specialist treat	ment	
	AKI of unclear etiology		
	Progressive AKI despite correction of pre-renal/p	oost renal factors	
	Kidney Transplant		
	Pre-existing advanced chronic kidney disease, e	GFR less than 30 mL/min/1.73 m2	
	Complications associated with AKI which may re	quire renal replacement therapy.	
	ction with liver failure or heart failure, hepatology/nephrology h immunosuppression for solid organ transplant.	or cardiology/nephrology consultations should be or	onsidered Consider consulting a transplant service when
Consult - Nephrology	Consult - Hepatology	Consult - Cardiology	Consult - Transplant
MD Consult	MD Consult	MD Consult	MD Consult







Study inquiries or feedback about the tools and processes?

Meha Bhatt, Project Coordinator meha.bhatt@ucalgary.ca